Advancements in targeted therapy for gastric cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: advanced-stage disease undergoing surgical resection, postoperative 5-year survival rates remain critically low, typically below 20%
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
These agents demonstrate significant potential in extending overall survival durations, underscoring their translational value and substantial research implications. This comprehensive review delineates recent advancements in GC-targeted therapies to inform precision oncology paradigms and guide future drug discovery initiatives.
Gastric cancer (GC) ranks among the most prevalent malignancies of the gastrointestinal system.
APA
Wang Y, Li J, et al. (2026). Advancements in targeted therapy for gastric cancer.. Therapeutic advances in gastroenterology, 19, 17562848261439234. https://doi.org/10.1177/17562848261439234
MLA
Wang Y, et al.. "Advancements in targeted therapy for gastric cancer.." Therapeutic advances in gastroenterology, vol. 19, 2026, pp. 17562848261439234.
PMID
42004816 ↗
Abstract 한글 요약
Gastric cancer (GC) ranks among the most prevalent malignancies of the gastrointestinal system. For patients with advanced-stage disease undergoing surgical resection, postoperative 5-year survival rates remain critically low, typically below 20%. Contemporary therapeutic strategies encompass surgical intervention, cytotoxic chemotherapy, immune checkpoint blockade, and molecularly-targeted agents. Targeted therapeutics exert their effects by exploiting molecular vulnerabilities such as human epidermal growth factor receptor-2, Claudin 18.2, vascular endothelial growth factor/vascular endothelial growth factor receptor, fibroblast growth factor receptor 2, and N6-methyladenosine modification pathways, thereby suppressing tumor proliferation and offering improved clinical outcomes for advanced GC. These agents demonstrate significant potential in extending overall survival durations, underscoring their translational value and substantial research implications. This comprehensive review delineates recent advancements in GC-targeted therapies to inform precision oncology paradigms and guide future drug discovery initiatives.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- "I wanna look like the person in that picture": Linking selfies on social media to cosmetic surgery consideration based on the tripartite influence model.
- ZmSKIP enhances drought tolerance by reducing stomatal aperture in maize.
- c.7374_7375insAlu is a French-Canadian founder pathogenic variant associated with predisposition to pancreatic and breast cancer.
- Enhancing Node-RADS for preoperative assessment of cervical lymph node metastases in papillary thyroid carcinoma: validation and modification.
- Aging modulation of the immune system and immunotherapy efficacy in cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.
- Revisiting the OGIPRO Trial: Dynamic Electronic Patient-Reported Outcomes Compared with EQ-5D-5L in HER2-Positive Breast Cancer.
- Prevalence and Outcomes of HER2-Low Versus HER2-0 Status in Patients with Metastatic Breast Cancer.
- Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer.
- Metformin triggers apoptosis via endoplasmic reticulum stress in HER2-positive breast cancer cell lines.
- Real-World Safety and Efficacy of Biosimilar Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer: A Prospective Single-Institution Study From India.